|
1
|
Lucore CL and Sobel BE: Interactions of
tissue type plasminogen activator with plasma inhibitors and their
pharmacologic implications. Circulation. 77:660–669. 1988.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sobel BE, Taatjes DJ and Schneider DJ:
Intramural plasminogen activator inhibitor type-1 and coronary
atherosclerosis. Arterioscler Thromb Vasc Biol. 23:1979–1989. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Eren M, Painter CA, Gleaves LA, Schoenhard
JA, Atkinson JB, Brown NJ and Vaughan DE: Tissue- and
agonist-specific regulation of human and murine plasminogen
activator inhibitor-1 promoters in transgenic mice. J Thromb
Haemost. 1:2389–2396. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Asakura T, Iwaki S, Okada H, Sobel BE and
Fujii S: Posttranscriptional regulation of expression of
plasminogen activator inhibitor type-1 by cAMP in HepG2 liver
cells. J Biochem. 150:687–694. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Iwaki S, Yamamura S, Asai M, Sobel BE and
Fujii S: Posttranscriptional regulation of expression of
plasminogen activator inhibitor type-1 by sphingosine 1-phosphate
in HepG2 liver cells. Biochim Biophys Acta. 1819:1132–1141. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chun J, Hla T, Lynch KR, Spiegel S and
Moolenaar WH: International union of basic and clinical
pharmacology. LXXVIII Lysophospholipid receptor nomenclature.
Pharmacol Rev. 62:579–587. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Spiegel S, English D and Milstien S:
Sphingosine 1-phosphate signaling: Providing cells with a sense of
direction. Trend Cell Biol. 12:236–242. 2002. View Article : Google Scholar
|
|
8
|
Spiegel S and Milistein S: Sphingosine
1-phosphate, a key cell signaling molecule. J Biol Chem.
277:25851–25854. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Takuwa Y, Okamoto Y, Yoshioka K and Takuwa
N: Sphingosine 1-phosphate signaling and biological activities in
the cardiovascular system. Biochem Biophys Acta. 1781:483–488.
2008.
|
|
10
|
Ito S, Iwaki S, Koike K, Yuda Y, Nagasaki
A, Ohkawa R, Yatomi Y, Furumoto T, Tsutsui H, Sobel BE and Fujii S:
Increased plasma Sphingosine 1-phosphate in obese individuals and
its capacity to increase the expression of plasminogen activator
inhibitor-1 in adipocytes. Coron Artery Dis. 24:642–650.
2013.PubMed/NCBI
|
|
11
|
Fink T, Kazlauskas A, Poellinger L,
Ebbesen P and Zachar V: Identification of a tightly regulated
hypoxia-response element in the promoter of human plasminogen
activator inhibitor-1. Blood. 99:2077–2083. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zagorska A and Dulak J: HIF-1: The knowns
and unknowns of hypoxia sensing. Acta Biochim Pol. 51:563–585.
2004.PubMed/NCBI
|
|
13
|
Ader I, Brizuela L, Bouquerel P, Malavaud
B and Cuvillier O: Sphingosine kinase 1: A new modulator of hypoxia
inducible factor 1alpha during hypoxia in human cancer cells.
Cancer Res. 68:8635–8642. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Leong WI and Saba JD: S1P metabolism in
cancer and other pathological conditions. Biochimie. 92:716–723.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cuvillier O and Ader I: Hypoxia-inducible
factors and sphingosine 1-phosphate signaling. Anticancer Agents
Med Chem. 11:854–862. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C (T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
17
|
Imagawa S, Fujii S, Dong J, Furumoto T,
Kaneko T, Zaman T, Satoh Y, Tsutsui H and Sobel BE: Hepatocyte
growth factor regulates E box-dependent plasminogen activator
inhibitor type 1 gene expression in HepG2 liver cells. Arterioscler
Thromb Vasc Biol. 26:2407–2413. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dong J, Fujii S, Li H, Nakabayashi H,
Sakai M, Nishi S, Goto D, Furumoto T, Imagawa S, Zaman TA and
Kitabatake A: Interleukin-6 and mevastatin regulate plasminogen
activator inhibitor-1 through CCAAT/enhancer-binding protein-δ.
Arterioscler Thromb Vasc Biol. 25:1078–1084. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Olivera A, Kohama T, Tu Z, Milstien S and
Spiegel S: Purification and characterization of rat kidney
sphingosine kinase. J Biol Chem. 273:12576–12583. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dimova EY, Jakubowska MM and Kietzmann T:
CREB binding to the hypoxia-inducible factor-I responsive elements
in the plasminogen activator inhibitor-I promotor mediates the
glucagon effect. Thromb Heamost. 98:296–303. 2007.
|
|
21
|
Dong J, Fujii S, Imagawa S, Matsumoto S,
Matsushita M, Todo S, Tsutsui H and Sobel BE: IL-1 and IL-6 induce
hepatocyte plasminogen activator inhibitor-1 expression through
independent signaling pathways converging on C/EBPdelta. Am J
Physiol Cell Physiol. 292:209–215. 2007. View Article : Google Scholar
|
|
22
|
Jung SY, Song HS, Park SY, Chung SH and
Kim YJ: Pyruvate promotes tumor angiogenesis through
HIF-1-dependent PAI-1 expression. Int J Oncol. 38:571–576.
2011.
|
|
23
|
Nakayama N, Nakamura T, Okada H, Iwaki S,
Sobel BE and Fujii S: Modulators of induction of plasminogen
activator inhibitor type-1 in HepG2 cells by transforming growth
factor-β. Coron Artery Dis. 22:468–478. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Anelli V, Gault CR, Cheng AB and Obeid LM:
Sphingosine kinase 1 is up-regulated during hypoxia in U87MG glioma
cells. Role of hypoxia-inducible factors 1 and 2. J Biol Chem.
283:3365–3375. 2008. View Article : Google Scholar
|
|
25
|
Michaud MD, Robitaille GA, Gratton JP and
Richard DE: Sphingosine-1-phosphate: A novel nonhypoxic activator
of hypoxia-inducible factor-1 in vascular cells. Arterioscler
Thromb Vasc Biol. 29:902–908. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kalhori V, Kemppainen K, Asghar MY,
Bergelin N, Jaakkola P and Törnquist K: Sphigosine-1-phosphate as a
regulator of hypoxia-induced factor-1α in thyroid follicular
carcinoma cells. PLoS One. 8:e661892013. View Article : Google Scholar
|
|
27
|
Brakch N, Dormond O, Bekri S, Golshayan D,
Correvon M, Mazzolai L, Steinmann B and Barbey F: Evidence for a
role of sphingosine-1 phosphate in cardiovascular remodelling in
Fabry disease. Eur Heart J. 31:67–76. 2010. View Article : Google Scholar
|
|
28
|
Moore DF, Kaneski CR, Askari H and
Schiffmann R: The cerebral vasculopathy of Fabry disease. J Neurol
Sci. 257:258–263. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Welch CL, Sun Y, Arey BJ, Lemaitre V,
Sharma N, Ishibashi M, Sayers S, Li R, Gorelik A, Pleskac N, et al:
Spontaneous atherothrombosis and medial degradation in
Apoe−/−, Npc1−/− mice. Circulation.
116:2444–2452. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yatomi Y, Igarashi Y, Yang L, Hisano N, Qi
R, Asazuma N, Satoh K, Ozaki Y and Kume S: Sphingosine 1-phosphate,
a bioactive sphingolipid abundantly stored in platelets, is a
normal constituent of human plasma and serum. J Biochem.
121:969–973. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hisano Y, Nishi T and Kawahara A: The
functional roles of S1P in immunity. J Biochem. 152:305–311. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hillmen P, Muus P, Dührsen U, Risitano AM,
Schubert J, Luzzatto L, Schrezenmeier H, Szer J, Brodsky RA, Hill
A, et al: Effect of the complement inhibitor eculizumab on
thromboembolism in patients with paroxysmal nocturnal
hemoglobinuria. Blood. 110:4123–4128. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Nguyen Dinh Cat A, Escoubet B, Agrapart V,
Griol-Charhbili V, Schoeb T, Feng W, Jaimes E, Warnock DG and
Jaisser F: Cardiomyopathy and response to enzyme replacement
therapy in a male mouse model for Fabry disease. PLoS One.
7:e337432012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Helley D, de Latour RP, Porcher R,
Rodrigues CA, Galy-Fauroux I, Matheron J, Duval A, Schved JF,
Fischer AM and Socié G; French Society of Hematology: Evaluation of
hemostasis and endothelial function in patients with paroxysmal
nocturnal hemoglobinuria receiving eculizumab. Haematologica.
95:574–581. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Anthony MT, Zeigler ZR, Lister J, Raymond
JM, Shadduck RK, Kramer RE, Gryn JF, Rintels PB, Besa EC, George
JN, et al: Plasminogen activator inhibitor (PAI-1) antigen levels
in primary TTP and secondary TTP post-bone marrow transplantation.
Am J Hematol. 59:9–14. 1998. View Article : Google Scholar : PubMed/NCBI
|
